Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Jun 30, 2026, 4:30 PM EDT - 20 days ago
LIMN
Jun 3, 2026, 8:30 AM EDT - 6 weeks ago
May 21, 2026, 8:28 PM EDT - 2 months ago
Mar 17, 2026, 8:08 AM EDT - 4 months ago
Feb 17, 2026, 8:44 AM EST - 5 months ago
Oct 30, 2025, 10:04 AM EDT - 9 months ago
Jul 28, 2025, 7:30 AM EDT - 1 year ago
Jul 25, 2025, 8:31 AM EDT - 1 year ago
Jul 24, 2025, 8:31 AM EDT - 1 year ago
Jul 22, 2025, 1:30 PM EDT - 1 year ago